CAJ | 학술논문

目的：检测NSCLC原发肿瘤和转移瘤中EGFR基因突变、基因扩增及KRAS基因突变情况，为临床靶向治疗提供更多的循证医学证据。方法：计算机文献检索中英文数据库，收集国内外公开发表的有关EG-FR-TKI靶向治疗预测性生物标记的文献研究，采用Cochrane协作网提供Review Manager 5.2软件进行Meta分析。结果：筛选文献，共11篇纳入研究。Meta分析结果显示，EGFR基因突变组、基因扩增组及KRAS基因突变组RR值分别为0.86（0.65-1.15）、0.73（0.44-1.20）及1.39（0.95-2.03）。结论：联合检测EGFR基因和KRAS基因在原发肿瘤中的突变情况，可作为EGFR-TKIs一线治疗较好的预测性生物标记。检测转移瘤中EGFR基因的扩增情况能够帮助进一步筛查哪些患者对靶向治疗更加敏感。
목적：검측NSCLC원발종류화전이류중EGFR기인돌변、기인확증급KRAS기인돌변정황，위림상파향치료제공경다적순증의학증거。방법：계산궤문헌검색중영문수거고，수집국내외공개발표적유관EG-FR-TKI파향치료예측성생물표기적문헌연구，채용Cochrane협작망제공Review Manager 5.2연건진행Meta분석。결과：사선문헌，공11편납입연구。Meta분석결과현시，EGFR기인돌변조、기인확증조급KRAS기인돌변조RR치분별위0.86（0.65-1.15）、0.73（0.44-1.20）급1.39（0.95-2.03）。결론：연합검측EGFR기인화KRAS기인재원발종류중적돌변정황，가작위EGFR-TKIs일선치료교호적예측성생물표기。검측전이류중EGFR기인적확증정황능구방조진일보사사나사환자대파향치료경가민감。
Objective:To determine EGFR mutation,EGFR gene amplification and KRAS mutation in primary and metastatic NSCLC in order to explore the implications in clinical practice. Methods:We searched the Chinese and English database to identify all the articles about the predictive biomarkers of EGFR-TKIs treatment. Meta-analysis was completed by Review Manager 5. 2 software. Results:11 literatrues were included in Meta-analysis. The RR in the group of EGFR mutation,EGFR gene amplification and KRAS mutation were 0. 86(0. 65-1. 15),0. 73(0. 44-1. 20)and 1. 39(0. 95-2. 03)respectively. Conclusion:Combined detection of KRAS and EGFR mutations in pri-mary NSCLC was considered to be the optimal approach to provide promising predictive biomarkers for targeted thera-py. EGFR amplification from metastatic tumors may be helpful for further identification of patients targeted therapy.